The Bengaluru-based skincare startup recorded 27.9% revenue growth, supported by product sales and expanding services, while lower advertising expenditure helped improve profitability.
CureSkin, a Bengaluru-based skincare and dermatology startup, reported revenue from operations of ₹133 crore in FY26, up 27.9% year-on-year. Its net loss narrowed 48.5% to ₹35 crore from ₹68 crore in FY25, as higher revenue and lower expenditure improved its financial performance.
The company provides personalised skincare and haircare solutions through digital consultations and products tailored to individual skin and hair concerns. Its business combines product sales with dermatology-led services.
Product sales remained its largest revenue source, contributing approximately 91% of operating revenue. Revenue from products increased 17.1% to ₹120.6 crore from ₹103 crore in FY25. Meanwhile, service revenue rose nearly ninefold to ₹12.4 crore, indicating a growing contribution from consultations and related offerings. Other income stood at ₹1 crore, taking total revenue to ₹134 crore.
A reduction in advertising and promotional expenditure helped improve the company’s financial performance. The expense fell 17.6% to ₹61 crore in FY26 from ₹74 crore a year earlier. Employee benefit expenses also declined 5.3% to ₹23.6 crore.
However, the cost of materials consumed increased 15.4% to ₹42 crore, while transportation expenses rose 30% to ₹13 crore. Miscellaneous expenses climbed 14.8% to ₹22.2 crore, although legal and professional charges declined 36.5% to ₹7.2 crore.
CureSkin’s EBITDA margin improved to -21.81% in FY26 from -60.94% in FY25. Its operating expenditure per rupee of revenue also decreased, with the company spending ₹1.27 to generate every rupee of operating revenue, compared with ₹1.69 previously. Despite this improvement, the business remained loss-making.
As of March 2026, CureSkin reported cash and bank balances of ₹8 crore and current assets of ₹40 crore, down from ₹72 crore a year earlier. The company has raised $26 million to date, including a $20 million funding round led by HealthQuad. Its other investors include JSW, Khosla Ventures and Sharrp Ventures.
Going forward, CureSkin’s challenge will be to sustain revenue growth while controlling customer acquisition costs. Expanding services revenue and maintaining spending discipline could help strengthen its business model as it works towards improved profitability.
Source: Based on publicly available reporting, with additional editorial adaptation and analysis.
